Literature DB >> 15036647

Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.

William A Brock1, Luka Milas, Sherry Bergh, Ruth Lo, Csaba Szabó, Kathy A Mason.   

Abstract

Inhibition of poly(ADP-ribose) polymerase (PARP) by a novel, potent inhibitor, INO-1001, was examined in two rodent and one human fibroblast cell lines, after single and fractionated radiation treatments. Since PARP plays a role in the early events following DNA damage and influences the effectiveness of DNA repair, its inhibition has been proposed to constitute a drug target for the development of novel radiosensitizers. We found that INO-1001 effectively inhibited PARP activity at non-cytotoxic concentrations. Combination treatment of 10 microM INO-1001 and a single dose of radiation resulted in significant radiosensitization of all three cells lines (enhancement ratios 1.4-1.6). This radioenhancement was even greater when the drug and radiation were given as fractionated treatments (enhancement ratio 8.0). Apoptosis (as evaluated by TUNEL staining) was not enhanced by the treatments, suggesting that inhibiting PARP enzyme activity by INO-1001 enhanced radiation-induced cell killing by interfering with DNA repair mechanisms, resulting in necrotic cell death. INO-1001 therefore, appears to have potential as a potent enhancer of radiation sensitivity, without any intrinsic cytotoxicity from the drug alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036647     DOI: 10.1016/j.canlet.2003.10.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

Review 1.  Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.

Authors:  David A Gewirtz; Moureq Alotaibi; Vasily A Yakovlev; Lawrence F Povirk
Journal:  Radiat Res       Date:  2016-09-02       Impact factor: 2.841

Review 2.  Targeting DNA repair and the cell cycle in glioblastoma.

Authors:  Brian M Alexander; Nancy Pinnell; Patrick Y Wen; Alan D'Andrea
Journal:  J Neurooncol       Date:  2011-11-24       Impact factor: 4.130

3.  MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.

Authors:  Li Wang; Kathy A Mason; K Kian Ang; Thomas Buchholz; David Valdecanas; Anjili Mathur; Carolyn Buser-Doepner; Carlo Toniatti; Luka Milas
Journal:  Invest New Drugs       Date:  2011-11-30       Impact factor: 3.850

Review 4.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

Review 5.  Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation.

Authors:  April M Reed; Melissa L Fishel; Mark R Kelley
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

Review 6.  Targeting poly(ADP-ribose) polymerase activity for cancer therapy.

Authors:  Frédérique Mégnin-Chanet; Marc A Bollet; Janet Hall
Journal:  Cell Mol Life Sci       Date:  2010-08-20       Impact factor: 9.261

Review 7.  Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

Authors:  Bryan P Rowe; Peter M Glazer
Journal:  Breast Cancer Res       Date:  2010-04-30       Impact factor: 6.466

Review 8.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

Review 9.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

10.  INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.

Authors:  Kathryn A Mason; David Valdecanas; Nancy R Hunter; Luka Milas
Journal:  Invest New Drugs       Date:  2007-07-13       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.